公开(公告)号：US20070154408A1

公开(公告)日：2007-07-05

申请号：US11684559

申请日：2007-03-09

Applicant: Himadri Sen ,  Suryakumar Jayanthi ,  Rakesh Sinha ,  Rolee Sharma ,  Pavan Muttil

Inventor： Himadri Sen ,  Suryakumar Jayanthi ,  Rakesh Sinha ,  Rolee Sharma ,  Pavan Muttil

IPC: A61K9/14

CPC classification number: A61K9/0075 ,  A61K9/0053 ,  A61K9/1647 ,  A61K31/00 ,  A61K31/445 ,  A61K31/455

Abstract: The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2:1, wherein the anti-tubercular drugs are in the ratio of 1:2 to 2:1, also, a process for the preparation of the composition, and lastly, a method of treating pulmonary tuberculosis in a subject, said method comprising administering by inhalation alone or in combination with oral route, pharmaceutically effective amount of the composition to the subject in need thereof, wherein the dosage for inhalation is ranging between 0.5 to 10 mg/kg body weight/day and that for oral route is ranging between 4 to 32 mg/kg body weight/day.

Abstract translation: 本发明涉及可用于目标特异性药物递送以管理肺结核的可生物降解的微粒组合物，所述组合物包含两种抗结核药物和用于药物递送的生物可降解聚合物，其比例为约1:2至2:1， 其中抗结核药物的比例为1:2至2:1，也是制备组合物的方法，最后是治疗受试者肺结核的方法，所述方法包括单独给药 或与口服途径组合的药物有效量的组合物与有需要的受试者组合，其中吸入剂量为0.5至10mg / kg体重/天，口服途径的范围为4至32mg / kg体重/天。

公开(公告)号：US20180169009A1

公开(公告)日：2018-06-21

申请号：US15577572

申请日：2016-06-01

Applicant: Patrick JOHNSON ,  C. Jeffrey BRINKER ,  Eric CARNES ,  Graham TIMMINS ,  Pavan MUTTIL ,  STC.UNM

Inventor： Patrick Johnson ,  C. Jeffrey Brinker ,  Eric Carnes ,  Graham Timmins ,  Pavan Muttil

IPC: A61K9/00 ,  A61K9/16 ,  A61K47/54 ,  C08L23/22 ,  A61K9/12 ,  A61K9/127

CPC classification number: A61K9/0073 ,  A61K9/12 ,  A61K9/1271 ,  A61K9/1617 ,  A61K47/543 ,  C08L23/22

Abstract: This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.

公开(公告)号：US20070154562A1

公开(公告)日：2007-07-05

申请号：US11684562

申请日：2007-03-09

Applicant: Himadri SEN ,  Suryakumar Jayanthi ,  Rakesh Sinha ,  Rolee Sharma ,  Pavan Muttil

Inventor： Himadri SEN ,  Suryakumar Jayanthi ,  Rakesh Sinha ,  Rolee Sharma ,  Pavan Muttil

IPC: A61K31/496 ,  A61K31/4965 ,  A61K9/14

CPC classification number: A61K9/0075 ,  A61K9/0053 ,  A61K9/1647 ,  A61K31/00 ,  A61K31/445 ,  A61K31/455

Abstract: The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2: 1, wherein the anti-tubercular drugs are in the ratio of 1:2 to 2:1, also, a process for the preparation of the composition, and lastly, a method of treating pulmonary tuberculosis in a subject, said method comprising administering by inhalation alone or in combination with oral route, pharmaceutically effective amount of the composition to the subject in need thereof, wherein the dosage for inhalation is ranging between 0.5 to 10 mg/kg body weight/day and that for oral route is ranging between 4 to 32 mg/kg body weight/day.

Abstract translation: 本发明涉及可用于目标特异性药物递送以管理肺结核的可生物降解的微粒组合物，所述组合物包含两种抗结核药物和用于药物递送的生物可降解聚合物，其比例为约1:2至2:1， 其中抗结核药物的比例为1:2至2:1，也是制备组合物的方法，最后是治疗受试者肺结核的方法，所述方法包括单独给药 或与口服途径组合的药物有效量的组合物与有需要的受试者组合，其中吸入剂量为0.5至10mg / kg体重/天，口服途径的范围为4至32mg / kg体重/天。